CoVigi phase IV multicentric trial evaluating COVID-19
vaccination effectiveness, safety, and immune response
dynamics: SARS-CoV-2-specific antibody and T-cell response
focused on patients with gastrointestinal tumors

a 2023

CoVigi phase IV multicentric trial evaluating COVID-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2-specific antibody and T-cell response focused on patients with gastrointestinal tumors

OBERMANNOVÁ, Radka; Iveta SELINGEROVÁ; Regina DEMLOVÁ; Dalibor VALÍK; Lenka ZDRAŽILOVÁ DUBSKÁ et. al.

Základní údaje

Originální název

CoVigi phase IV multicentric trial evaluating COVID-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2-specific antibody and T-cell response focused on patients with gastrointestinal tumors

Autoři

OBERMANNOVÁ, Radka (203 Česká republika, garant); Iveta SELINGEROVÁ (203 Česká republika, domácí); Regina DEMLOVÁ (203 Česká republika, domácí); Dalibor VALÍK (203 Česká republika, domácí); Lenka ZDRAŽILOVÁ DUBSKÁ (203 Česká republika, domácí) a Igor KISS (203 Česká republika, domácí)

Vydání

2023

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30230 Other clinical medicine subjects

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Kód RIV

RIV/00216224:14110/23:00131953

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.annonc.2023.04.432

UT WoS

001037960400377

Klíčová slova česky

COVID-19; Solid cancer; multicentric trial;

Klíčová slova anglicky

COVID-19; Solid cancer; multicentric trial;

Štítky

Excelence Science, MOÚ, MU

Příznaky

Mezinárodní význam

Změněno: 2. 11. 2023 14:02, Mgr. Tereza Miškechová

Anotace

V originále

Solid cancer patients are at high risk of a more severe course of COVID-19, especially those undergoing active anti-cancer therapy causing immunosuppression. Vaccination is still the only option to prevent serious events associated with SARS-CoV-2 infection. We aim to assess adverse effects, efficacy, and immune response against SARS-CoV-2 in cancer patients, focusing on comparison with healthy volunteers and possible interfering therapy.

Návaznosti

LM2023049, projekt VaV

Název: Český národní uzel Evropské sítě infrastruktur klinického výzkumu

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CZECRIN - Czech National Node to the European Clinical Research Infrastructure Network

Citovat

OBERMANNOVÁ, Radka; Iveta SELINGEROVÁ; Regina DEMLOVÁ; Dalibor VALÍK; Lenka ZDRAŽILOVÁ DUBSKÁ a Igor KISS. CoVigi phase IV multicentric trial evaluating COVID-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2-specific antibody and T-cell response focused on patients with gastrointestinal tumors. 2023. Dostupné z: https://dx.doi.org/10.1016/j.annonc.2023.04.432.

@proceedings{2327137,
   author = {Obermannová, Radka and Selingerová, Iveta and Demlová, Regina and Valík, Dalibor and Zdražilová Dubská, Lenka and Kiss, Igor},
   doi = {http://dx.doi.org/10.1016/j.annonc.2023.04.432},
   keywords = {COVID-19; Solid cancer; multicentric trial;},
   language = {eng},
   title = {CoVigi phase IV multicentric trial evaluating COVID-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2-specific antibody and T-cell response focused on patients with gastrointestinal tumors},
   url = {https://www.sciencedirect.com/science/article/pii/S0923753423005744?via%3Dihub},
   year = {2023}
}

TY  - CONF
ID  - 2327137
AU  - Obermannová, Radka - Selingerová, Iveta - Demlová, Regina - Valík, Dalibor - Zdražilová Dubská, Lenka - Kiss, Igor
PY  - 2023
TI  - CoVigi phase IV multicentric trial evaluating COVID-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2-specific antibody and T-cell response focused on patients with gastrointestinal tumors
KW  - COVID-19
KW  - Solid cancer
KW  - multicentric trial;
UR  - https://www.sciencedirect.com/science/article/pii/S0923753423005744?via%3Dihub
N2  - Solid cancer patients are at high risk of a more severe course of COVID-19, especially those undergoing active anti-cancer therapy causing immunosuppression. Vaccination is still the only option to prevent serious events associated with SARS-CoV-2 infection. We aim to assess adverse effects, efficacy, and immune response against SARS-CoV-2 in cancer patients, focusing on comparison with healthy volunteers and possible interfering therapy.
ER  -

OBERMANNOVÁ, Radka; Iveta SELINGEROVÁ; Regina DEMLOVÁ; Dalibor VALÍK; Lenka ZDRAŽILOVÁ DUBSKÁ a Igor KISS. \textit{CoVigi phase IV multicentric trial evaluating COVID-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2-specific antibody and T-cell response focused on patients with gastrointestinal tumors}. 2023. Dostupné z: https://dx.doi.org/10.1016/j.annonc.2023.04.432.

Přehled o publikaci